- The FDA approved Provention Bio Inc’s PRVB Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years and older who currently have stage 2 type 1 diabetes.
- Tzield binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. Tzield may deactivate the immune cells that attack insulin-producing cells while increasing the proportion of cells that help moderate the immune response. Tzield is administered by intravenous infusion once daily for 14 consecutive days.
- Tzield’s safety and efficacy were evaluated in a 76-patient trial. The trial results showed that over a median follow-up of 51 months, 45% of the 44 patients who received Tzield were later diagnosed with stage 3 type 1 diabetes, compared to 72% of the 32 patients who received a placebo.
- The therapy narrowly passed the vote at an FDA advisory committee meeting in May last year amid questions about the small study size and more.
- The FDA hit teplizumab with a complete response letter, rejecting the application, in June last year.
- After resubmitting the marketing application, the FDA extended the review period by three months.
- In October, the company announced a co-promotion agreement for the U.S. launch of Tzield for the delay in the onset of clinical T1D in at-risk individuals with Sanofi SA SNY.
- Teplizumab was previously developed by MacroGenics Inc MGNX, which PRVB licensed in May 2018.
- Under the agreement, MacroGenics is entitled to receive $60 million upon FDA approval.
- Price Action: PRVB shares are 4.37% higher at $8.60 premarket on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
